Endometrial Cancer

Oncology·MeSH: Endometrial Neoplasms

Prevalence

58.0 / 100K

Incidence

28.0 / 100K/yr

26 drugs in development·17 companies·83 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
Jemperli	ANAPTYSBIO, INC (ANAB)

Phase 3(11)

Drug	Company
BNT323/DB-1303	BioNTech SE (BNTX)
datopotamab deruxtecan	ASTRAZENECA PLC (AZN)
incagn02390	Incyte Corp. (INCY)
ONC201	Jazz Pharmaceuticals plc (JAZZ)
premedication	Genmab A/S (GMAB)
puxitatug samrotecan	ASTRAZENECA PLC (AZN)
Rilvegostomig	Merus N.V. (MRUS)
rina-s	GENMAB A/S (GNMSF)
Rina-S	Merus N.V. (MRUS)
tsr-042	TESARO, Inc. (TSRO)
Volrustomig	ASTRAZENECA PLC (AZN)

Phase 2(4)

Drug	Company
DKN-01	Merck & Co., Inc. (MRK)
incagn02385	Incyte Corp. (INCY)
Lifileucel	IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
ONA-XR	Context Therapeutics Inc. (CNTX)

Phase 1(3)

Drug	Company
hwk-007	Whitehawk Therapeutics, Inc. (WHWK)
imgn151	ImmunoGen, Inc. (IMGN)
IMGN151	AbbVie Inc. (ABBV)

Preclinical(2)

Drug	Company
ost-tadc	OS Therapies Inc (OSTX)
ost-tadc-a	OS Therapies Inc (OSTX)

Early Phase 1(1)

Drug	Company
Dendritic Cell Vaccine	Merus N.V. (MRUS)

Phase 1/Phase 2(3)

Phase 4(1)

Drug	Company
Tirzepatide	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 26 drugs in development for Endometrial Cancer across 17 companies.

There are 83 clinical trials targeting Endometrial Cancer tracked by BioSniper.

The estimated prevalence of Endometrial Cancer is approximately 58.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.